SecBot SecBot
8-K ·Filed Nov 9, 2026

NKTX

Nkarta, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed7d 15h ago SEC0001787400-26-000027
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

Watch for upcoming FDA interactions to define registrational pathways and for 1H 2027 data on additional follow-up and registrational dose selection (4B vs 6B cells/dose). The compressed dosing schedule and dose escalation are key catalysts.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.59
T+0 close · Nov 9, 2026 · via day close
Latest settled
−23.90%
T+5 · $1.21
Vs SPY
−22.21%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $1.59entry
  2. T+1 · 7d ago −15.09%α −14.73% · $1.35
  3. T+5 · 18h ago −23.90%α −22.21% · $1.21
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nkarta reported initial Phase 1/2 clinical data for NKX019, an allogeneic CAR NK cell therapy, in myositis and systemic sclerosis at ACR Convergence 2026. At the 4 billion cells per dose level, 83% of myositis patients and 86% of systemic sclerosis patients achieved clinically meaningful responses, with a favorable safety profile (no CRS, ICANS, or GvHD in 40 patients). The company plans FDA interactions for registrational pathways and expects additional data in 1H 2027.

Key Facts

  • In myositis, 5/6 (83%) patients at 4B cells/dose with >=3 months follow-up achieved moderate or major TIS responses.
  • In systemic sclerosis, 6/7 (86%) patients at 4B cells/dose achieved rCRISS-25 or greater by Day 90; 5/7 (71%) achieved rCRISS-50 or greater.
  • Median mRSS reduction of 15 points at Day 90 in SSc; 5/7 (71%) achieved >=50% reduction from baseline.
  • No deaths, no treatment discontinuations due to AEs, no CRS, ICANS, IEC-HS, or GvHD among 40 patients across five indications.
  • Company amended Ntrust protocols to compress dosing to Days 0, 2, 4 and plans to evaluate 6B cells/dose.
  • Company anticipates FDA interactions to discuss registrational pathways in both myositis and systemic sclerosis.
  • Cash, cash equivalents and investments of $216M as of Sep 30, 2026; expected cash runway into 2029.

Financial Impact

No revenue or earnings data; clinical-stage biotech with $216M cash runway into 2029. Positive efficacy and safety data could support regulatory path and valuation.

Risk Factors

  • Preliminary data from small patient numbers with limited follow-up; results may change as more data become available.
  • FDA may not agree with proposed registrational pathways or dose selection.
  • Changes to dosing schedule or dose level may not achieve anticipated results or may raise safety concerns.
  • No head-to-head studies vs other therapies; cross-trial comparisons are cautioned.
  • Company has no approved products and a history of losses; dependent on NKX019 clinical success.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001787400-26-000027
Document: nktx-ex99_1.htm0001787400-26-000027
Document: nktx-ex99_2.htm0001787400-26-000027
Document: 0001787400-26-000027-index-headers.html0001787400-26-000027
Document: 0001787400-26-000027-index.html0001787400-26-000027
Document: 0001787400-26-000027.txt0001787400-26-000027

Track record

13 reports on NKTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  2. Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  3. Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
  6. Aug 10, 202614w ago 8-K Bearish 6/10 Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
  7. May 12, 202626w ago Press Release Neutral 4/10 Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
  8. Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
  9. Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
  10. Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026